Evome Medical Technologies Inc (EVMT) Fair Value & Analysis
Healthcare · CA · Market cap C$414K
Fair value as of: Jul 5, 2026
From 1 valuation models · updated 39 days ago
Fair value updated Jul 5, 2026, revised from C$0.0068 to C$0.0063 (−6.7%) since Jun 26, 2026.
Below-average quality, screening 26% undervalued on our models.
What matters now
- The price is below even our cautious bear case (C$0.0058). The market is more pessimistic than our downside scenario.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 5, 2026.
How to read this chart
60‑month range C$0.0050 – C$1.41 · fair‑value band C$0.0058 – C$0.0073 · the C$0.0050 price screens below the C$0.0063 fair value. Dashed = 300-day average. As of Jul 5, 2026.
Analysis
Evome Medical Technologies Inc (EVMT) currently trades at C$0.0050, while our model-based Fair Value estimate is C$0.0063, implying the stock looks roughly 26.0% undervalued today. The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Evome Medical Technologies Inc generated revenue of C$48.3M at a net margin of -48.7%. Revenue declined 49.0% year over year. Fundamentals as of Jul 5, 2026
Our scenario range runs from C$0.0058 (bear case) to C$0.0073 (bull case); at C$0.0050, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at 26%, EVMT screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when EVMT reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 41
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Evome Medical Technologies Inc. designs, develops, produces, and sells medical devices in the United States. The company was formerly known as Salona Global Medical Device Corporation and changed its name to Evome Medical Technologies Inc. in January 2024. The company is based in Shirley, New York.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Evome Medical Technologies Inc reported revenue of C$62.6M in FY2023 versus C$352K in FY2019, a compound +265.2%/yr. Reported net income was −C$15.6M in FY2023.
Watch EVMT: get an alert when its fair value changes →
Peer Group
Medical Devices · 349 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare Evome Medical Technologies Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Evome Medical Technologies Inc (EVMT) overvalued or undervalued?
What is the fair value of EVMT?
What is the quality score of EVMT?
What is the revenue of Evome Medical Technologies Inc (EVMT)?
What is the net profit margin of EVMT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Evome Medical Technologies Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.